Free Trial
NASDAQ:ARVN

Arvinas (ARVN) Stock Price, News & Analysis

Arvinas logo
$7.72 +0.49 (+6.78%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$7.64 -0.08 (-0.97%)
As of 05/2/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arvinas Stock (NASDAQ:ARVN)

Key Stats

Today's Range
$6.80
$8.00
50-Day Range
$6.19
$18.28
52-Week Range
$5.94
$37.38
Volume
8.59 million shs
Average Volume
1.25 million shs
Market Capitalization
$530.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.82
Consensus Rating
Moderate Buy

Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Arvinas Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

ARVN MarketRank™: 

Arvinas scored higher than 66% of companies evaluated by MarketBeat, and ranked 242nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 12 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arvinas has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arvinas' stock forecast and price target.
  • Earnings Growth

    Earnings for Arvinas are expected to grow in the coming year, from ($3.81) to ($3.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arvinas is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arvinas is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arvinas has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.86% of the float of Arvinas has been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arvinas has recently increased by 20.97%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Arvinas does not currently pay a dividend.

  • Dividend Growth

    Arvinas does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.86% of the float of Arvinas has been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arvinas has recently increased by 20.97%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Arvinas has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 30 news articles for Arvinas this week, compared to 6 articles on an average week.
  • Search Interest

    Only 12 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $769,402.00 in company stock.

  • Percentage Held by Insiders

    Only 5.23% of the stock of Arvinas is held by insiders.

  • Percentage Held by Institutions

    95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arvinas' insider trading history.
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

Jefferies Downgrades Arvinas (ARVN)
What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.
Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript
See More Headlines

ARVN Stock Analysis - Frequently Asked Questions

Arvinas' stock was trading at $19.17 at the beginning of 2025. Since then, ARVN stock has decreased by 59.7% and is now trading at $7.72.
View the best growth stocks for 2025 here
.

Arvinas, Inc. (NASDAQ:ARVN) issued its earnings results on Thursday, May, 1st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.93) by $2.07. The company's revenue for the quarter was up 646.2% compared to the same quarter last year.
Read the conference call transcript
.

Arvinas (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Top institutional investors of Arvinas include Bank of New York Mellon Corp (0.25%), Banque Pictet & Cie SA (0.14%), Rhumbline Advisers (0.13%) and Assenagon Asset Management S.A. (0.12%). Insiders that own company stock include John G Houston, Sean A Cassidy, Ian Taylor, Noah Berkowitz, Ronald Peck and David K Loomis.
View institutional ownership trends
.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/01/2025
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
420
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.82
High Stock Price Target
$69.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+234.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
19 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-198,900,000.00
Pretax Margin
-75.29%

Debt

Sales & Book Value

Annual Sales
$263.40 million
Price / Cash Flow
N/A
Book Value
$8.17 per share
Price / Book
0.94

Miscellaneous

Free Float
65,175,000
Market Cap
$530.92 million
Optionable
Optionable
Beta
2.30
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ARVN) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners